Latest Content

Domestic manufacturing can reduce certain dependencies, but reliable pharmaceutical commercialization requires qualified redundancy, sustainable economics, quality maturity and decision-ready visibility across the full supply network.

Access leaders are pressed to prove AI ROI, but ConnectiveRx execs Cindy Baksh and Steve Randall argue the real work is defining "better" first, then deciding where AI fits.

In this week's Pharma Pulse, Infinitus launches an AI-first hub model, EVERSANA is tapped to commercialize Innovacell's regenerative cell therapy in the US, Peli BioThermal and PAXAFE pair packaging with predictive cold chain intelligence, and Ember LifeSciences strikes a distribution alliance with Japan's top pharma wholesaler.

Ember LifeSciences and Alfresa, Japan's top pharma wholesaler, form a cold chain alliance as biologics and specialty distribution demand grows.

Gifthealth's Chip Parkinson shares his outlook on direct-to-patient models in specialty, regulation and platform design heading into 2027.

Four pharma commerce experts revisit their 2026 predictions on dealmaking, patient access and commercialization at the year's midpoint.

Gifthealth's Chip Parkinson says direct-to-patient adoption has accelerated since January, driven by structural, not cyclical, market forces.

Peli BioThermal and PAXAFE are partnering to pair cold chain packaging with AI-powered monitoring, signaling where pharma logistics technology is headed next.

Gifthealth's Chip Parkinson revisits his 2026 outlook on the direct-to-patient model, and what's developed in H1.

Amy Niles of the Patient Advocate Foundation on the Medicare Part D cap, Medicaid, ACA exchanges and rural hospital access in late 2026.

Geopolitical instability is pushing life sciences firms to map supply chains beyond suppliers to protect trials and patient access.

How commercial trade groups are shifting from distribution execution to strategic partners shaping market access, launch readiness and commercial performance.

Cencora's Brent Wilhelm on how specialty drug growth, cold chain demand, and reimbursement pressure are pushing distributors toward centralized safety stock and AI-driven flexibility.